长春高新：控股子公司两款药品被新纳入国家医保目录

Core Viewpoint - Changchun Gaoxin (000661) announced on December 8 that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has successfully included its independently developed Jin Sai Zeng (now known as "Jin Pei Growth Hormone Injection") and the collaboratively introduced Mei Shi Ya (known as "Acetate Medroxyprogesterone Oral Suspension") in the national medical insurance catalog for 2025 [1] Group 1 - Changchun Gaoxin's subsidiary has developed Jin Sai Zeng, which is now part of the national medical insurance catalog [1] - The company has also introduced Mei Shi Ya into the national medical insurance catalog [1]